Journal of Clinical Oncology
Articles in this Issue
A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer, (HCRN GU18-343) ABATE study.
800 Background: Atezolizumab (A) has demonstrated single agent activity as neoadjuvant therapy (NAT) for muscle invasive urothelial carcinoma (MIUC) (ABAC...
OCOG-RATIONAL: A phase II randomized trial of optimal recurrence-directed therapy (RDT) without or with androgen-deprivation therapy (ADT) in radio-recurrent oligo-metastatic castrate sensitive prostate cancer (romCSPC).
TPS305 Background: This is a Canadian, multi-center study that investigates whether addition of ADT to RDT improves oncological outcomes in early romCSPC....
A phase III study testing the role of proactive coaching on patient reported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of axitinib + pembrolizumab or avelumab in first line therapy (PREPARE; AIO-NZK-0115/ass).
523 Background: Tyrosine kinase (TKI) and immune checkpoint inhibitors (CPI) are first-line options in metastatic renal cell carcinoma (mRCC). Most patien...
Population-adjusted network meta-analyses (NMA) to evaluate the efficacy of treatment alternatives for metastatic hormone-sensitive prostate cancer (mHSPC).
267 Background: Existing NMA in mHSPC compare treatments assuming homogeneity in treatment effect modifiers across study populations. However, evidence su...
Phase I dose-escalation study of the next-generation nectin-4 targeting antibody–drug conjugate CRB-701 (SYS6002) in US and UK patients with urothelial cancer and other solid tumors.
807 Background: Linker conjugation chemistry is a key determinant of antibody–drug conjugate (ADC) activity and tolerability. Linkers must be stable in th...
The prognostic utility of preoperative β2 microglobulin in patients with renal cell carcinoma.
565 Background: β2 microglobulin is a nonglycosylated protein synthesized by all nucleated cells. It has been utilized as a tumor marker in several differ...
Sociodemographic predictors of the late-stage diagnosis in patients with prostate cancer: A retrospective cohort study.
132 Background: Distant metastasis at the time of prostate cancer (PCa) diagnosis is associated with increased morbidity and mortality. This study aimed t...
Approach to treatment of metastatic hormone-sensitive prostate (mHSPC) cancer among cooperative oncology groups (CCTG, SWOG, and Alliance) in North America.
263 Background: Randomized clinical trials have demonstrated the efficacy of both doublet (androgen deprivation therapy (ADT) + androgen receptor pathway...
A novel predictive model using changes in clinical and serum biomarkers and automated quantitative imaging for mCRPC patients treated with AR-directed therapy.
264 Background: In mCRPC, standard risk models use baseline clinical and blood-based biomarkers, excluding imaging. This study developed a new predictive...
Cancer-control outcomes of metastatic castration resistant prostate cancer patients with <i>BRCA</i> -gene or tumor suppressor mutations undergoing 177-lutetium PSMA radioligand therapy.
71 Background: Several tumor gene mutations are known for metastatic castration-resistant prostate cancer (mCRPC) are known. The individual response to 17...
Feasibility and efficacy of cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer in older patients: A retrospective French GETUG study.
735 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) and radical cystectomy is the gold standard in localized muscle-invasive bladder cancer (MI...
Leveraging tumor organoids to model drug response in clear cell renal cell carcinoma.
579 Background: Clear cell renal cell carcinoma (ccRCC) is characterized by a highly immunosuppressive tumor microenvironment that plays a crucial role in...
Early findings from a national quality improvement (QI) program to address disparities in bladder cancer (BLCA) care.
697 Background: Rates of guideline-concordant treatment for BLCA remain <50%, driven by access and care delivery barriers. The Association of Cancer Ca...
A novel CD28 x Nectin-4 costimulatory bispecific antibody for advanced bladder cancer.
810 Background: Effective T-cell activation is driven by multiple signals. CD3 bispecific antibodies (bsAbs) stimulate T-cell activation through the TCR....
Management strategies and patient outcomes among LPC patients with persistently positive PSA after RP.
353 Background: Patients (pts) with localized high-risk/very high-risk prostate cancer (PCa) have an elevated risk of metastases and Prostate Cancer (PC)-...
PSA dynamics: Enhancing predictive models in prostate cancer follow-up.
424 Background: Advances in prostate cancer (PC) care have led to a 98% 10-year survival rate. Prostate Specific Antigen (PSA) is the primary method of fo...
Use of geospatial analysis with multiplex immunofluorescence to analyze tumor immune microenvironment patterns and prognosis in penile cancer.
12 Background: Previous studies utilizing multiplex Immunofluorescence (mIF) have described cell density patterns of immune exhaustion implicating both in...
Chromosomal instability in tumor suppressor genes–altered prostate cancer.
226 Background: Metastatic prostate cancer (PC) accumulates significant genomic alterations as the disease progresses, exhibiting the highest levels of ch...
Modeling survival outcomes of KEYNOTE-564 with standard of care control arm treatment: A simulation study.
517 Background: The KEYNOTE-564 study, reporting improved overall survival (OS) with use of adjuvant checkpoint inhibitor (CPI), pembrolizumab, following...
Spatial analysis of the immune microenvironment and identification of phenotypes of prognostic significance in penile squamous cell carcinoma (PSCC).
13 Background: Advanced penile cancer is a rare but aggressive malignancy. Over 70% of patients with bulky metastases relapse or have primary refractory d...
Impact of adjuvant intraarterial chemotherapy on survival for patients with stage IIIA-IIIB bladder urothelial carcinoma after radical cystectomy: An open-label, prospective, randomized clinical trial.
772 Background: The aim of this trial was to evaluate the survival benefit of adjuvant intraarterial chemotherapy (IAC) in patients who received radical c...
Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP): A comparison of enzalutamide vs abiraterone acetate.
131 Background: Whether treatment with androgen receptor pathway inhibitors (ARPIs) with distinct mechanisms of action and central nervous system (CNS) pe...
A phase 1b/2 study evaluating the activity of tinengotinib in combination with androgen receptor pathway inhibitors (ARPIs) in patients with metastatic castration resistant prostate cancer (mCRPC).
TPS290 Background: Androgen receptor pathway inhibitors (ARPIs) are standard life-prolonging therapies for patients with metastatic castration-resistant p...
Reduction of systemic chemotherapy by primary retroperitoneal lymph node dissection in low volume metastatic seminoma.
626 Background: Still, standard treatment of low-volume metastatic semimoma is either systemic chemotherapy or radiotherapy. Both options are associated w...
Real-world effectiveness and treatment (tx) patterns in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) receiving avelumab first-line maintenance (1LM) in Japan: Results from the JAVEMACS chart review study.
701 Background: Avelumab 1LM was approved in Feb 2021 in Japan based on results of the JAVELIN Bladder 100 phase 3 trial, which showed prolonged overall s...